Here, we have approached this question through the lens of BRCA-mutant prostate cancer which, in contrast to breast and ovarian cancer, is largely a BRCA2-mutant disease with a higher percentage of somatic rather than germline cases, as well as frequent 13q copy number loss spanning the BRCA2 gene. This evidence concerns the gene BRCA2 and Familial prostate cancer.